Navigation Links
'Gadonanotubes' greatly outperform existing MRI contrast agents

Researchers at Rice University, the Baylor College of Medicine, the University of Houston and the Ecole Polytechnique Fédérale de Lausanne in Switzerland have created a new class of magnetic resonance imaging (MRI) contrast agents that are at least 40 times more effective than the best in clinical use.

The new agents -- dubbed gadonanotubes -- use the same highly toxic metal, gadolinium, that is given to more than a quarter of MRI patients today, but the metal atoms are encased inside a hollow tube of pure carbon called a nanotube. Shrouding the toxic metals inside the benign carbon is expected to significantly reduce or eliminate the metal's toxicity.

The research was published this month in the journal Chemical Communications.

"In prior work, we have boosted the effectiveness of gadolinium MRI contrast agents by encasing them in spheres of carbon called buckyballs," said lead author Lon Wilson, professor of chemistry at Rice. "Each nanotube will hold more gadolinium atoms than a buckyball, so we expected them to be more effective agents. But they are actually much, much better than we anticipated, so much so that no existing theory can explain how they work."

Wilson and colleagues use short segments of nanotubes, tiny cylinders of pure carbon about one billionth of a meter, or one nanometer, in diameter. That's about as wide as a strand of DNA. The ultrashort segments are only about 20-100 times longer than they are wide, and once inside the nanotubes, the gadolinium atoms naturally aggregate into tiny clusters of about 10 atoms each. Wilson and colleagues suspect the clustering is causing the unexplained increases in magnetic and MRI effects that they observed in tests at Rice, at the University of Houston's Texas Center for Superconductivity, and in the Swiss laboratories.

More than 25 million patients in the U.S. undergo MRIs each year. Doctors use contrast agents in about 30 percent of MRIs. The contrast agents increase t he sensitivity of the scans, making it easier for doctors to deliver a diagnosis. Gadolinium agents are the most effective agents and the most commonly used.

In the future, the researchers hope to use existing methods of attaching disease-specific antibodies and peptides to gadonanotubes so they can be targeted to cancerous tumors and other diseased cells.

Co-authors include Rice's Balaji Sitharaman, Kyle Kissell, Keith Hartman and Lesa Tran; the University of Houston's Andrei Baikalov, Irene Rusakova and Yanyi Sun; the Baylor College of Medicine's Htet Khant, Steven Ludtke and Wah Chiu; and the Ecole Polytechnique Fédérale's Sabrina Laus, Eva Tóth, Lothar Helm and André Merbach.


'"/>

Source:Rice University


Related biology news :

1. Low oxygen likely made Great Dying worse, greatly delayed recovery
2. Survival of heart patients on beta-blockers varies greatly with genetic variation
3. Access to existing medical treatments could save more lives than spending to improve the treatments
4. Got inexpensive contrast agent? Milk plays new role in imaging
5. Tiny avalanche photodiodes target bioterrorism agents
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... ON (PRWEB) , ... June 23, 2016 , ... STACS ... DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as ... the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology: